BioWorld

March 22, 2002

Alkermes Buying Reliant In Stock Purchase Worth $934M

Scooping up the shares it doesn’t already own, Alkermes Inc. agreed to purchase the remaining 81 percent of Reliant Pharmaceuticals LLC in a stock deal worth about $934 million. (BioWorld Today) Read More

PDL’s Stock Up 22 Percent On Poor Phase II Results

Test Ships Amyloid-Beta Plaques From Brain To Blood, Forecasts Alzheimer’s Onset Years Ahead

Ligand, Elan Get FDA Nod For Pain Treatment Avinza

Other News To Note

Cell Genesys Drops Gene Therapy Collaboration With GPC Biotech

Hemosol’s Stock Falls 29 Percent After Hemolink Denial In Canada

Today's news in brief

BioWorld

BioWorld briefs for June 22, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Nankai University and Accendatech present new majusculamide D derivatives

BioWorld Science

Scientists from Nankai University Tianjin and Accendatech Technology Co. Ltd. have identified a majusculamide D derivative found to be useful for the treatment of...

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...